Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 290 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Imatinib Mesylate Clear all
Completed Phase 4 Interventional

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

NCT01742299
View directory record Official record
Conditions
GIST and CML
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 7, 2026, 10:29 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

NCT00323063
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine hydrochloride, imatinib mesylate
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Camden, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

NCT00028002
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Conventional Surgery, Imatinib Mesylate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00470470
View directory record Official record
Conditions
Acral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Miami Beach, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 7, 2026, 10:29 AM EDT
Completed No phase listed Observational

Role of Gene Variation in Effectiveness of Gleevec Treatment

NCT00342056
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 7, 2026, 10:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105
View directory record Official record
Conditions
GIST
Interventions
Ripretinib, Sunitinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
20
States / cities
La Jolla, California • New Haven, Connecticut • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

NCT00400569
View directory record Official record
Conditions
Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma
Interventions
Sunitinib Malate (SU011248)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis

NCT00512902
View directory record Official record
Conditions
Alveolitis, Systemic Sclerosis
Interventions
Imatinib
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

NCT00027586
View directory record Official record
Conditions
Melanoma, Skin Neoplasms
Interventions
Imatinib mesylate (STI571)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

NCT00025246
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 1 Interventional

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

NCT00611689
View directory record Official record
Conditions
Refractory Malignancy, Solid Tumors
Interventions
Imatinib and PTK/ZK222584
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 7, 2026, 10:29 AM EDT
Terminated Phase 1 Interventional

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

NCT01397734
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Arsenic trioxide
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

NCT00039585
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 7, 2026, 10:29 AM EDT
Active, not recruiting Phase 2 Interventional

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

NCT00044304
View directory record Official record
Conditions
Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome
Interventions
Imatinib, Ruxolitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 7, 2026, 10:29 AM EDT
Terminated Phase 2 Interventional Results available

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

NCT02709083
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Leukemia
Interventions
Dasatinib, Imatinib Mesylate, Nilotinib
Drug
Lead sponsor
Emory University
Other
Eligibility
17 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 1 Interventional

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

NCT00390156
View directory record Official record
Conditions
Unspecified Adult Solid Tumor
Interventions
bevacizumab, cyclophosphamide, imatinib
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00471497
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic
Interventions
nilotinib, imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Vallejo, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

NCT00171223
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
STI571
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

NCT01083589
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Imatinib Mesylate, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

NCT00661180
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nexavar (Sorafenib, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

NCT00038610
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Mesna, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 7, 2026, 10:29 AM EDT
Terminated Phase 2 Interventional Results available

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

NCT01391611
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Pazopanib
Drug
Lead sponsor
Kristen Ganjoo
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

NCT00363649
View directory record Official record
Conditions
Leukemia
Interventions
GM-K562 cell vaccine, Interferon alfa, Sargramostim
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 7, 2026, 10:29 AM EDT
Completed Phase 1 Interventional Results available

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

NCT02508532
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
Interventions
Avapritinib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 7, 2026, 10:29 AM EDT